This article was originally published in The Gray Sheet
Completes the divestiture of its contact lens business with the sale of contact lens operations outside the Americas to U.K.- based Hydron. In late 1992, the firm sold its North and South American contact lens business to Ocular Sciences ("The Gray Sheet" Nov. 9, I&W-13). Terms of the Hydron transaction were not disclosed, but Allergan reports that "an immaterial gain was realized." Allergan President and CEO William Shepherd said that the firm "remain[s] committed" to its contact lens care products business.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.